文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

乌干达一线抗逆转录病毒治疗12和48个月后病毒载量抑制率、失败预测因素及耐药模式

Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究采用WHO横断面调查方案,在乌干达纳入547名治疗12个月和1064名治疗≥48个月的一线ART成人患者,检测病毒载量并对病毒学失败者进行基因型耐药检测。结果显示12个月和48个月病毒载量抑制率分别为95.0%和87.9%,而病毒学失败者中获得性耐药患病率分别高达96.1%和90.4%,提示在推荐的三次强化依从性咨询和重复病毒载量检测之前,耐药已高度流行。

要点

  • 治疗12个月和48个月病毒载量抑制率分别为95.0%和87.9%。
  • 病毒学失败者中获得性耐药患病率在12个月和48个月组分别达96.1%和90.4%。
  • 48个月组中,齐多夫定起始方案和ART时长≥82个月是耐药独立预测因素。

核心结论

  • 病毒载量抑制率整体良好,但病毒学失败者在接受推荐的三次强化依从性咨询和重复病毒载量检测之前,获得性耐药患病率已极高,提示治疗切换前的强化依从性咨询对改善病毒载量抑制可能获益有限。

研究设计与样本

  • 采用WHO横断面调查方案,纳入547名一线ART治疗12(±3)个月的成人(ADR12组)和1064名治疗≥48个月的成人(ADR48组),收集干血斑和血浆标本用于病毒载量检测,并对病毒学失败者(VL≥1000 copies/mL)进行基因型耐药检测。

主要发现

  • ADR12组病毒载量抑制率为95.0%(95%CI 93.4%-96.5%),ADR48组为87.9%(95%CI 85.0%-90.9%)。
  • ADR12组获得性耐药加权患病率为96.1%(95%CI 72.9%-99.6%),基于30例成功基因型;ADR48组为90.4%(95%CI 73.6%-96.8%),基于95例成功基因型。
  • 在ADR48组中,与替诺福韦为基础方案相比,齐多夫定为基础方案起始与病毒学失败显著相关,AOR 1.96(95%CI 1.13-3.39)。
  • ADR48组中获得性耐药的独立预测因素包括:与替诺福韦为基础方案相比,齐多夫定为基础方案起始(AOR 3.16,95%CI 1.34-7.46);与ART时长<82个月相比,≥82个月(AOR 1.92,95%CI 1.03-3.59)。

临床怎么用

  • 在病毒学失败者中,获得性耐药高度流行,提示治疗切换前的强化依从性咨询对改善病毒载量抑制可能有限,应结合耐药检测结果优化治疗决策。
  • 齐多夫定为基础的一线方案和较长ART时长与病毒学失败及获得性耐药风险升高相关,临床应加强此类患者的病毒载量监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We implemented the WHO cross-sectional survey protocol to determine rates of HIV viral load (VL) suppression (VLS), and weighted prevalence, predictors and patterns of acquired drug resistance (ADR) in individuals with virological failure (VF) defined as VL ≥1000 copies/mL. METHODS: We enrolled 547 and 1064 adult participants on first-line ART for 12 (±3) months (ADR12) and ≥48 months (ADR48), respectively. Dried blood spots and plasma specimens were collected for VL testing and genotyping among the VFs. RESULTS: VLS was 95.0% (95% CI 93.4%-96.5%) in the ADR12 group and 87.9% (95% CI 85.0%-90.9%) in the ADR48 group. The weighted prevalence of ADR was 96.1% (95% CI 72.9%-99.6%) in the ADR12 and 90.4% (95% CI 73.6-96.8%) in the ADR48 group, out of the 30 and 95 successful genotypes in the respective groups. Initiation on a zidovudine-based regimen compared with a tenofovir-based regimen was significantly associated with VF in the ADR48 group; adjusted OR (AOR) 1.96 (95% CI 1.13-3.39). Independent predictors of ADR in the ADR48 group were initiation on a zidovudine-based regimen compared with tenofovir-based regimens, AOR 3.16 (95% CI 1.34-7.46) and ART duration of ≥82 months compared with <82 months, AOR 1.92 (95% CI 1.03-3.59). CONCLUSIONS: While good VLS was observed, the high prevalence of ADR among the VFs before they underwent the recommended three intensive adherence counselling (IAC) sessions followed by repeat VL testing implies that IAC prior to treatment switching may be of limited benefit in improving VLS.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ssemwanga D, Asio J, Watera C, et al. Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda. J Antimicrob Chemother. 2020. PMID: 32025714. doi:10.1093/jac/dkz561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。